Isolation and Characterization of Galactose from Hydrolysates of Glycogen

Biotransformation of diclofenac and effects on the metabolome of primary human hepatocytes upon repeated dose exposure

In vitro repeated dose testing for the assessment of chronic drug-induced effects is a huge challenge in preclinical pharmaceutical drug development. Chronic toxicity results in discontinuation of therapy or post-marketing withdrawal of drugs despite in vivo preclinical screening. In case of hepatotoxicity, due to limited long term viability and functionality of primary hepatocytes, chronic hepatic effects are difficult to detect. In this study, we maintained primary human hepatocytes in a serum-free cultivation medium for more than 3 weeks and analyzed physiology, viability and drug metabolizing capacities of the hepatocytes. Moreover, we assessed acute (24 h) diclofenac toxicity in a range of (10-1000 μM) concentrations. The chronic (9 repeated doses) toxicity at one clinically relevant and another higher concentration (6.4 and 100 μM) was also tested. We investigated phase I and II metabolism of diclofenac upon repeated dose exposure and analyzed effects on the cellular exometabolome. Acute 24 h assessment revealed toxicity only for the highest tested concentration (1 mM). Upon repeated dose exposure, toxic effects were observed even at a low, clinically relevant concentration (6.4 μM). Biotransformation pathways were active for 3 weeks and diclofenac-acylglucuronide was detected as the predominant metabolite. Dose dependent diclofenac-induced effects on exometabolome, such as on the production of lactate and 3-hydroxybutyric acid as well as glucose and galactose metabolism, were observed upon nine repeated doses. Summarizing, we show that repeated dose testing on long-term functional cultures of primary human hepatocytes may be included for the assessment of long term toxic effects in preclinical screening and can potentially help replace/reduce in vivo animal testing.

Metabolism of galactose in the brain and liver of rats and its conversion into glutamate and other amino acids

Time- and dose-dependent measurements of metabolites of galactose (with glucose as control) in various organs of rats are discussed. Not only the liver but especially the brain and to a lesser extent the muscles also have the capacity to take up and metabolize galactose. Primarily, the concentrations of UDP-galactose, a pivotal compound in the metabolism of galactose, and UDP-glucose are measured. An important feature lies in the demonstration that galactose and glucose are metabolized to amino acids and that the only increases observed in the brain appear in the concentrations of glutamate, glutamine, GABA measured after acute galactose loads. In addition the increase in the amino acid concentrations after galactose has been administered persists for longer periods of time than after glucose administration. This conversion of hexoses, especially galactose, to amino acids requires the consumption of ammonia equivalents in the brain; this finding might stimulate the use of galactose as a new means of removal of this neurotoxic compound from the brain in patients suffering from hepatic encephalopathy or Alzheimer's disease.

Glycogenesis in the amphibian retina: in vitro conversion of [2-3H]mannose to [3H]glucose and subsequent incorporation into glycogen

We previously demonstrated by light and electron microscopic autoradiography that Xenopus retinas incubated with [3H]mannose exhibit tunicamycin-insensitive radiolabeling of glycogen storage compartments, especially cone parabaloids. In the present study, we utilized biochemical methods to evaluate the identity of the material presumed to be [3H]glycogen in Xenopus retinas obtained from eyecups incubated under similar conditions. A crude glycogen-containing fraction was isolated, solubilized with 8 M urea, and purified by Sepharose CL-4B column chromatography. The retinal glycogen was hydrolyzed either chemically or with specific amylolytic enzymes, followed by Sephacryl S-200 column chromatography and HPLC of the hydrolysis products. Under the conditions employed, [3H]glycogen represented at least 10% of the total radiolabeled macromolecules. Hydrolysis of the [3H]glycogen released all of the radiolabel in the form of [3H]glucose, not [3H]mannose, which indicated that direct incorporation of [3H]mannose into glycogen had not occurred. [3H]Glucose was distributed throughout the glycogen molecule, not just in the outer tiers, which indicated that de novo glycogenesis had occurred. Furthermore, enzymatic isomerization of the glycogen-derived [3H]glucose with glucose isomerase yielded fructose with retention of tritium. This demonstrated that positions other than the C-2 carbon of glucose were radiolabeled. Analysis of the medium after several hours of incubation revealed the presence of 3H2O as the major radiolabeled compound. These results support the conclusion that the in vitro incorporation of [2-3H]mannose into retinal glycogen involves initial catabolism of the radiolabeled substrate and subsequent reincorporation of the label via gluconeogenesis into precursors utilized for de novo glycogenesis.

D-[3H]galactose incorporation into glycogen in retinal cone cells

Previous studies have shown that bovine retinas incubated with [3H]galactose incorporated it, unmodified, into large molecules. Light and electron microscope autoradiography showed a significant proportion of the label to be in cone inner segments, and pulse-chase studies showed it was subsequently transported to the synaptic pedicles. In this report, evidence is presented to show that the galactose-labelled macromolecules are resistant to hydrolysis by proteolytic enzymes, testicular hyaluronidase, chondroitinase ABC, beta-glucosidase and beta-glucuronidase, but are readily degraded by alpha-amylase and beta-galactosidase, and to a lesser extent by beta-amylase. Treatment with alpha-amylase also leads to specific removal of radioactivity from cone inner segments and pedicles, as judged by light-microscopic autoradiography. These studies appear to indicate that the cone-specific galactose label is in glycogen or glycogen-like molecules.

Ordered synthesis and degradation of liver glycogen involving 2-amino-2-deoxy-D-glucose

The incorporation of 2-amino-2-deoxy-D-glucose from precursor 2-amino-2-deoxy-D-galactose into liver glycogen has been shown to be a metabolically inhomogeneous process after starvation. The protein-to-polysaccharide ratio is also heterogeneous with respect to molecular size, and enhanced overall as compared to normal glycogen. The results are discussed from the viewpoint of a molecular order in the synthesis and degradation of liver glycogen.